Would concurrent CRLF2/IgH rearrangement affect your treatment recommendations for an adult patient with Ph+ p190 high risk (Age>35, WBC >30) B-cell ALL that was started on induction therapy with ponatinib + blinatumomab?
Comorbidities: morbid obesity, diabetes, hypertension
Community PollStarted
Outside of a clinical trial, my/our preferred initial treatment for a fit and non-elderly adult with Ph+ ALL is:
6 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Washington
Answered on
Short answer: No.
Longer answer: We lack a clear understanding of how to change treatment for adults with CRLF2 fusions with Ph- ALL, and this is the situation where it is more clearly understood to have prognostic significance (Roberts et al., PMID 27870571). In my view, it would be very difficult ...
Join for free or sign in to see the full answer